摘要
目的 研究羟甲戊二酰辅酶A还原酶抑制剂 (他汀类药物 )普拉固对延缓慢性肾衰进展的临床疗效。方法 选择非糖尿病肾病的慢性肾脏病患者共 48例 ,随机分成两组 ,在原有基础治疗上治疗组 2 6例患者予以普拉固治疗 ,对照组 2 2例单纯予以基础治疗 ,分别在 0 ,1,6,12个月时监测血脂、血清肌酐、肌酐清除率、尿视黄醇结合蛋白和尿蛋白定量。结果 与对照组相比 ,普拉固组血脂有显著下降 (P <0 0 5 ) ,而且尿视黄醇结合蛋白和尿蛋白水平有显著下降 (P <0 0 1) ,从 6月始治疗组肌酐上升幅度明显减缓 (P <0 0 5 )。一年后治疗组肌酐明显低于对照组 (P <0 0 1)。
Objective To study the effect of pravastatin on the patients with chronic renal failure(CRF)and normal blood lipid. Methods 48 cases of CRF patients with normal blood lipid were randomly divided into two groups. 26 patients of group 1 were given pravastatin besides basic treatment. 22 patients of group 2 were only given basic treatment. The treatment was consecutive for one year. Blood lipid, serum creatinine, clearance rate of serum creatinine(Ccr), urinary retinol-binding protein(RBP) and protein amount in urine were tested respectively before treatment and one month, six months and one year after the treatment. Results Compared with the patients of group 2, blood lipid, urinary RBP and total urinary proteins and serum creatinne decreased, and Ccr increased in the patients of group 1. Conclusion Pravastatin can postpone the renal dysfunction of the CRF patients with nomal blood lipid.
出处
《中国医师杂志》
CAS
2004年第8期1026-1027,共2页
Journal of Chinese Physician
关键词
普拉固
非糖尿病肾病
肾功能衰竭
高脂血症
hydroxy-3-methylglutaryl CoA reductase inhibitor
Chronic renal failure
Non-diabetic nephropathy
Pravastatin
